Table 4 Overview of treatment-emergent adverse events in the safety population
3003 ApoE ε4 carrier study | 3002 ApoE ε4 noncarrier study | |||||
|---|---|---|---|---|---|---|
PBO + BAP 0.5 (n = 215) | BAP 0.5 + BAP 0.5 (n = 275) | PBO + BAP 0.5 (n = 39) | PBO + BAP 1.0 (n = 37) | BAP 0.5 + BAP 0.5 (n = 66) | BAP 1.0 + BAP 1.0 (n = 56) | |
Any TEAE | 152 (70.7) | 184 (66.9) | 32 (82.1) | 25 (67.6) | 48 (72.7) | 36 (64.3) |
Any SAE | 35 (16.3) | 33 (12.0) | 6 (15.4) | 1 (2.7) | 10 (15.2) | 11 (19.6) |
TEAE leading to treatment discontinuation | 18 (8.4) | 10 (3.6) | 2 (5.1) | 2 (5.4) | 5 (7.6) | 6 (10.7) |
TEAE leading to study discontinuation | 14 (6.5) | 10 (3.6) | 2 (5.1) | 1 (2.7) | 1 (1.5) | 1 (1.8) |
TEAE leading to dose reduction or temporary discontinuation | 18 (8.4) | 10 (3.6) | 2 (5.1) | 3 (8.1) | 1 (1.5) | 4 (7.1) |